✦ LIBER ✦

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

✍ Scribed by I. Lang; M.J. Inbar; Z. Kahán; R. Greil; S. Beslija; S.M. Stemmer; B. Kaufman; Z. Zvirbule; G.G. Steger; D. Messinger; T. Brodowicz; C. Zielinski

Book ID: 119233293
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 302 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.04.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

A randomized phase III trial of paclitax

A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100

✍ R. Zon; Miller; M. Wang; J. Gralow; M. Dickler; M. Cobleigh; E. Perez; T. Shenki 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Efficacy and safety of bevacizumab in co

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO

✍ Xavier Pivot; Andreas Schneeweiss; Shailendra Verma; Christoph Thomssen; José Lu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 531 KB

257 Design of RESILIENCE: a Phase 3 TRia

257 Design of RESILIENCE: a Phase 3 TRial Comparing CapecitabinE in Combination with SorafenIb or PLacebo for Treatment of Locally Advanced or MetastatIc HER2-Negative Breast CancEr

✍ J. Baselga; F. Costa; H. Gomez; C. Hudis; B. Rapoport; H. Roche; L.S. Schwartzbe 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

275 ORAL First-line bevacizumab and pacl

275 ORAL First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 262 KB

Phase II Interventional Study (N0337) of

Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial

✍ Winston W. Tan; Jacob B. Allred; Muhammad Salim; Patrick Flynn; Paul A.S. Fishki 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 354 KB